SaniMed Science Group
SaniMed Science Group is a global life science investment and commercialization firm focused on Biotech, MedTech, TechBio, and AI-enabled healthcare innovations. We invest in and partner with early- and growth-stage companies developing differentiated technologies with clear clinical and regulatory pathways.
Leveraging deep expertise in FDA/NMPA strategy, preclinical and IND-enablement planning, clinical development, medical device engineering, and cross-border execution, SaniMed helps portfolio companies accelerate product readiness, reduce development risk, and strengthen global regulatory positioning.
Through our international network of hospitals, CRO/CDMOs, engineering partners, and research institutions, SaniMed supports founders with cost-efficient resources for R&D, IND-enabling studies, clinical trials, prototyping, and manufacturing across the U.S. and Asia.
Our mission is to back transformative science and enable global commercialization that delivers meaningful, long-term healthcare impact.
Meet Our Team
Jim Wu, MD, MBA
CEO & Managing Director
Mr. Jim Wu is a healthcare investor and entrepreneur with extensive experience leading SaniMed Science Group, where he focuses on Biotech, MedTech, TechBio, and AI-health startups. He specializes in evaluating high-potential scientific platforms and supporting founders through strategic capital, FDA/NMPA regulatory insight, IND-enabling strategy, and cross-border execution across the U.S. and Asia. His investment approach spans direct deals, SPVs, and selective LP commitments, collaborating with institutional funds and global innovation networks to accelerate development and commercialization.
Mr. Wu is a Lifetime Founding Member of BULLPEN, actively mentoring founders and supporting diligence and SPV structuring. He also participates in the Alumni Ventures investment network, Propel(x), and other U.S.–Asia syndicates, strengthening his access to global deal flow. As the founder of several technology and global commercialization companies, he completed the Founder Institute HealthTech Core Program, further enhancing his capabilities in early-stage venture building.
Prior to founding SaniMed, he held roles in international trade, procurement, outsourcing, and business development. He earned his M.D. from Peking University Health Science Center and an MBA from the University of Houston.
Alexander A. Oraevsky, PhD
Technology Advisor
Dr. Alexander A. Oraevsky, internationally known as the "Father of Biomedical Optoacoustic Imaging," has dedicated over 30 years to the research and industrial translation of biomedical optoacoustic imaging technology. He has received funding of nearly $20 million from US Government such as the National Institutes of Health (NIH) and The Department of Defense. He is the primary inventor on 22 patents, including the world's first patent on the optoacoustic imaging method entitled "Method and System for Optoacoustic Imaging." He has also published 11 book chapters and over 200 research papers. He has been honored with the Berthold Leibinger Innovations Prize and the James Smith Award from the International Photoacoustic and Photothermal Association. Currently, Dr. Alexander serves as the CEO and CTO of TomoWave Laboratories, Inc., where he focuses on the development and commercialization of high-resolution, high-contrast, and high-sensitivity 3D quantitative optoacoustic tomography (qOAT) systems for applications in oncology and vascular diseases. He also holds the positions of Chairman and CEO at TomoWave (Suzhou) Medical Imaging Co., Ltd., an adjunct professor in the Department of Biomedical Engineering at the University of Houston. Furthermore, Dr. Alexander has held various positions throughout his career, including being a board member and Chief Scientific Officer at Seno Medical Instruments, Director of the Optoacoustic Imaging and Spectroscopy Laboratory at the Biomedical Engineering Center of the University of Texas Medical Branch at Galveston, Research Assistant professor in the Department of Electrical and Computer Engineering at Rice University, Distinguished Professor of Medical Imaging at Guangzhou Medical University. and the Santander Chair of Excellence in Electronics at Carlos III University of Madrid. Dr. Alexander graduated from the Moscow Engineering Physics Institute with a master's degree in ultrafast laser spectroscopy of biomolecules in 1980, and with a doctoral degree in spectroscopy, photochemistry, and biophysics from the Institute of Spectroscopy of the Russian Academy of Sciences in 1986.
Gary Carruthers, BSBA
Market Advisor
Gary Carruthers is a seasoned leader in gastrointestinal (GI) medical technologies with over 30 years of hands-on experience in the U.S. MedTech industry. He spent more than two decades at Medtronic—the world’s largest medical device company—where he held key national leadership roles, including National Clinical Education Manager, Principal Market Development Manager, and National Account Director. At Medtronic, Gary spearheaded the nationwide commercialization of breakthrough GI technologies such as EndoFLIP, led cross-functional teams across clinical, regulatory, and commercial domains, and played a pivotal role in integrating acquired companies into Medtronic’s U.S. operations and product systems.
Widely recognized for his ability to translate complex clinical needs into FDA-compliant, market-ready solutions, Gary excels at bridging communication and execution among physicians, product developers, regulators, and payers. His strategic insight spans the entire product lifecycle—from early-stage design and regulatory planning to hospital procurement, market access, and reimbursement strategy. He has guided numerous stakeholders in bringing innovative medical devices to the U.S. market, achieving both clinical adoption and commercial success.
Beyond his domestic expertise, Gary is also a respected global advisor. He partners with international MedTech firms to successfully navigate the complexities of the U.S. healthcare system. His deep knowledge of compliance standards, reimbursement frameworks, and clinical integration makes him a trusted resource for global market entry. Whether coordinating FDA submissions, crafting U.S. launch strategies, or optimizing payer engagement, Gary consistently delivers practical, high-impact solutions tailored to the real-world demands of MedTech commercialization.
Can Cui, PhD, JD
Legal Advisor
Dr. Can Cui is a trusted legal advisor to SaniMed, bringing deep expertise in life sciences and medical technology law. With a strong focus on cross-border technology transactions, investments, and intellectual property (IP) strategy, Dr. Cui advises clients across the full lifecycle of innovation—from early-stage discovery to clinical development and commercialization. Dr. Cui represents a wide range of clients, including global pharmaceutical companies, biotech startups, and medical technology ventures, in complex licensing, collaboration, and joint venture transactions. He has particular experience advising on U.S.-China cross-border deals, and his work spans technology transfer, contract manufacturing, clinical trials, distribution, and commercialization agreements.
In the investment sphere, Dr. Cui regularly conducts IP due diligence and negotiates deal terms for venture capital and private equity transactions, advising both investors and life sciences companies. He also counsels on IP aspects of mergers and acquisitions, ensuring the protection and strategic use of core technologies. With dual insight into both U.S. and Chinese legal and regulatory frameworks, Dr. Cui provides clients with practical guidance on IP law, technology import/export, foreign investment regulations, and data privacy compliance. His scientific training, combined with years of legal practice, enables him to bridge technical innovation and legal strategy effectively.
As a long-standing advisor to biotech startups accelerated by H7 BioCapital, Dr. Cui also supports early-stage companies in navigating market entry, fundraising, and growth, serving as a key partner from concept to Series A and beyond.
